HomeABUS • NASDAQ
add
Arbutus Biopharma Corp
Previous close
$3.16
Day range
$3.00 - $3.17
Year range
$2.63 - $4.72
Market cap
582.10M USD
Avg Volume
1.17M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 1.57M | -26.62% |
Operating expense | 8.43M | 65.30% |
Net income | -12.53M | 35.11% |
Net profit margin | -796.19 | 11.57% |
Earnings per share | -0.10 | 38.71% |
EBITDA | -15.34M | 23.94% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 122.62M | -2.68% |
Total assets | 131.71M | -8.79% |
Total liabilities | 34.34M | -10.53% |
Total equity | 97.37M | — |
Shares outstanding | 191.48M | — |
Price to book | 6.20 | — |
Return on assets | -28.79% | — |
Return on capital | -36.08% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | -12.53M | 35.11% |
Cash from operations | -10.32M | 40.35% |
Cash from investing | 13.41M | -39.66% |
Cash from financing | 1.42M | -62.67% |
Net change in cash | 4.48M | -48.78% |
Free cash flow | -10.96M | -18.93% |
About
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. Wikipedia
Founded
2007
Headquarters
Website
Employees
44
